Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study

• Published in: PloS one Vol. 13; no. 5; p. e0197148
• Main Authors: Chachaj, Angelika, Wiśniewski, Jerzy, Rybka, Justyna, Butrym, Aleksandra, Biedroń, Monika, Krzystek-Korpacka, Małgorzata, Fleszar, Mariusz Grzegorz, Karczewski, Maciej, Wróbel, Tomasz, Mazur, Grzegorz, Gamian, Andrzej, Szuba, Andrzej
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 22-05-2018; Public Library of Science (PLoS)
• Subjects: Acute myelocytic leukemia; Acute myeloid leukemia; Atherosclerosis; Biochemistry; Biology and Life Sciences; Blood cancer; Bone marrow; Cancer patients; Cardiovascular disease; Cardiovascular diseases; Cell cycle; Chemical properties; Chronic lymphocytic leukemia; Complications and side effects; Diabetes; Diagnosis; Health aspects; Health risk assessment; Heart attacks; Hematology; Homocysteine; Immunology; Internal medicine; Kidney diseases; Leukemia; Lymphatic leukemia; Lymphoma; Malignancy; Medicine and Health Sciences; Metabolites; Mortality; Myeloid leukemia; Nitric oxide; Oxidative stress; Patient outcomes; Patients; Risk factors; Rodents; Systematic review; Transplants & implants; Tumors; Poland
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0197148

The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5-53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58-5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91-11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients.